Reported 1 day ago
TransMedics Group, Inc. (NASDAQ:TMDX) has garnered positive attention from Wall Street following its conditional FDA approval for the Next-Generation OCS ENHANCE Heart trial, which aims to enhance heart graft viability. Analysts have reaffirmed 'Buy' ratings with significant price targets, indicating strong support for the company's innovative approach to organ transplant technology.
Source: YAHOO